mirror of
https://github.com/MBombeck/HealthLog.git
synced 2026-11-13 14:32:03 +00:00
Marc-André Bombeck
4f09c3f862
v1.4.27 — Mobile capability and maintainer-finding cleanup. ResponsiveSheet primitive (bottom-sheet on narrow viewports, centred dialog on desktop) applied to BD, Weight, Glucose, Mood, Activity forms. Maintainer-finding cleanups across Coach, Insights, Reports, Privacy. GeoLite2 offline geocoding with resilience layer (graceful fallback when EULA not yet propagated). E2E gap-fill coverage. 450-line release notes attached to the GitHub Release.
613 lines
21 KiB
TypeScript
613 lines
21 KiB
TypeScript
/**
|
||
* v1.4.25 W19a — GLP-1 EMA drug knowledge layer.
|
||
*
|
||
* Read-only static reference data for the five EMA-approved GLP-1
|
||
* receptor agonists (and one dual GIP/GLP-1 agonist). Values are
|
||
* extracted verbatim from EMA EPAR Product Information PDFs and
|
||
* cross-validated against the journal-of-record population PK paper
|
||
* for tirzepatide (Schneck & Urva 2024, DOI 10.1002/psp4.13099).
|
||
*
|
||
* Posture (per `.planning/research/glp1-feature-inspiration.md` §11):
|
||
* - Display only. No autonomous dose escalation, no individual
|
||
* weight-loss projection, no drug-drug interaction checking,
|
||
* no mixing/reconstitution math.
|
||
* - Coach must NEVER reason from these numbers as if they were
|
||
* individual predictions; GROUND RULE 9 still applies.
|
||
* - Retatrutide is deliberately excluded — no EMA approval as of
|
||
* 2026-05; including it would imply endorsement of unauthorised
|
||
* use (N7).
|
||
*
|
||
* Sources:
|
||
* - EMA EPAR PDFs linked per drug below.
|
||
* - Schneck KB, Urva S. "Population pharmacokinetics of the GIP/GLP
|
||
* receptor agonist tirzepatide." CPT Pharmacometrics Syst
|
||
* Pharmacol. 2024;13(3):494-503. DOI 10.1002/psp4.13099.
|
||
*
|
||
* Numbers are pinned exactly per the research file's §1.1–§1.5 and
|
||
* the psp4.13099 cross-validation in §2.6. Drift introduces clinical
|
||
* risk; see `__tests__/glp1-knowledge-drift.test.ts` for the guard.
|
||
*/
|
||
|
||
/**
|
||
* Internal drug ids — stable across schema migrations. Brand-aware
|
||
* UI looks up by id, not by brand name.
|
||
*/
|
||
export type Glp1DrugId =
|
||
| "tirzepatide"
|
||
| "semaglutide"
|
||
| "liraglutide"
|
||
| "dulaglutide"
|
||
| "exenatide";
|
||
|
||
/**
|
||
* Route enum — most agonists are subcutaneous; Rybelsus is oral
|
||
* semaglutide. The catalog records the default route on the drug
|
||
* record AND a per-brand override map so a single drug-id can carry
|
||
* mixed routes (semaglutide → Ozempic/Wegovy sc, Rybelsus oral).
|
||
*/
|
||
type Glp1Route = "subcutaneous" | "oral";
|
||
|
||
/**
|
||
* Drug class descriptor — Tirzepatide is the only dual GIP/GLP-1
|
||
* agonist among EMA-approved agents (2026-05); the rest are pure
|
||
* GLP-1 receptor agonists.
|
||
*/
|
||
type Glp1DrugClass = "GIP-GLP1 dual agonist" | "GLP-1 receptor agonist";
|
||
|
||
type Glp1Pharmacology = {
|
||
/** Terminal elimination half-life. Days for the long-acting agents,
|
||
* hours for liraglutide / short-acting exenatide. */
|
||
halfLifeDays: number;
|
||
/** Time to maximum concentration after a SC dose, hours. Liraglutide
|
||
* uses the EMA EPAR §5.2 mean (~11 h); the weekly agents use the
|
||
* pharmacology-text midpoint of their EMA-published 8–72 h range. */
|
||
tmaxHours: number;
|
||
/** First-order absorption rate constant. Populated from the
|
||
* journal-of-record where one exists (tirzepatide ←
|
||
* Schneck/Urva 2024); marked null where EMA does not publish a
|
||
* pop-PK Ka estimate (the EPARs cite only terminal half-life). */
|
||
absorptionRateHourlyKa: number | null;
|
||
/** SC bioavailability, fraction in [0,1]. EMA EPAR §5.2 values. */
|
||
bioavailability: number;
|
||
/** Volume of distribution per kg body weight. Derived from the
|
||
* EPAR's reported Vd at a 70 kg reference where the source gives
|
||
* an absolute litre value. */
|
||
vdLitersPerKg: number;
|
||
/** Apparent clearance at the 70 kg reference weight, L/h. From
|
||
* EPAR §5.2 or the journal-of-record where available. */
|
||
clearanceLPerHour70kg: number;
|
||
/** Weeks until steady-state plateau on the standard cadence. */
|
||
steadyStateWeeks: number;
|
||
/** Compartment model that best describes published PK. The
|
||
* research-view curve (R8, deferred to v1.5) will honour this. */
|
||
compartmentModel: "one-compartment" | "two-compartment";
|
||
};
|
||
|
||
type Glp1Storage = {
|
||
/** Refrigerated stability — every GLP-1 product is shipped 2–8 °C
|
||
* per EMA. */
|
||
unopened: {
|
||
temperatureCelsius: { min: number; max: number };
|
||
};
|
||
/** Post-opening / in-use window. EMA §6.3 caps every product at
|
||
* ≤ 30 °C; the day-count varies by product. */
|
||
inUse: {
|
||
temperatureCelsius: { min: number; max: number };
|
||
maxDays: number;
|
||
};
|
||
};
|
||
|
||
type Glp1Pen = {
|
||
/** Pen device name as printed on the carton. */
|
||
type: string;
|
||
/** Doses per pen / per cartridge — drives W19b inventory
|
||
* depletion math. `null` means single-use (one pen per dose). */
|
||
dosesPerPen: number | null;
|
||
};
|
||
|
||
type Glp1AdverseReactions = {
|
||
/** ≥ 1/10 frequency per EMA §4.8. */
|
||
veryCommon: readonly string[];
|
||
/** 1/100 to <1/10 per EMA §4.8. */
|
||
common: readonly string[];
|
||
/** 1/1 000 to <1/100 per EMA §4.8. */
|
||
uncommon: readonly string[];
|
||
/** < 1/1 000 per EMA §4.8 — typically post-marketing signals. */
|
||
rare: readonly string[];
|
||
};
|
||
|
||
type Glp1Indications = {
|
||
t2dm: { firstLine: boolean };
|
||
weightManagement: { bmiThreshold: number | null };
|
||
};
|
||
|
||
type Glp1SourceCitations = {
|
||
/** Direct link to the EMA EPAR product-information PDF. */
|
||
sourceEMA: string;
|
||
/** Peer-reviewed pharmacometric citation where one exists. */
|
||
sourceJournal?: {
|
||
citation: string;
|
||
doi: string;
|
||
};
|
||
};
|
||
|
||
export type Glp1DrugRecord = {
|
||
inn: string;
|
||
brands: readonly string[];
|
||
/** Default route for the drug; brand-specific overrides go in
|
||
* `brandRoutes`. */
|
||
route: Glp1Route;
|
||
/** Per-brand route override map. Only populated when at least one
|
||
* brand departs from the default route (e.g. Rybelsus is oral
|
||
* semaglutide while Ozempic / Wegovy are SC). */
|
||
brandRoutes?: Readonly<Record<string, Glp1Route>>;
|
||
drugClass: Glp1DrugClass;
|
||
pharmacology: Glp1Pharmacology;
|
||
/** Standard titration ladder in mg. Strictly ascending. The
|
||
* schedule is informational per EMA EPAR §4.2 — the UI surfaces
|
||
* it for context, never as autonomous escalation guidance (N1). */
|
||
titrationStepsMg: readonly number[];
|
||
/** Minimum interval between titration steps per EMA §4.2. */
|
||
titrationIntervalWeeks: number;
|
||
maxDoseMg: number;
|
||
standardInjectionFrequency: "daily" | "twice-daily" | "weekly";
|
||
indications: Glp1Indications;
|
||
storage: Glp1Storage;
|
||
pen: Glp1Pen;
|
||
sideEffects: Glp1AdverseReactions;
|
||
contraindications: readonly string[];
|
||
warnings: readonly string[];
|
||
} & Glp1SourceCitations;
|
||
|
||
/**
|
||
* The catalog. Five drug records keyed by stable id. Brand-name
|
||
* lookup is one-to-many; route-mapping is exposed both as the
|
||
* record default and the per-brand override.
|
||
*/
|
||
export const GLP1_DRUGS: Readonly<Record<Glp1DrugId, Glp1DrugRecord>> = {
|
||
// §1.1 — Tirzepatide. EMA EPAR cross-validated against
|
||
// Schneck & Urva 2024 (psp4.13099). Two-compartment first-order
|
||
// absorption + elimination per the journal-of-record.
|
||
tirzepatide: {
|
||
inn: "Tirzepatide",
|
||
brands: ["Mounjaro", "Zepbound"],
|
||
route: "subcutaneous",
|
||
drugClass: "GIP-GLP1 dual agonist",
|
||
pharmacology: {
|
||
halfLifeDays: 5.0,
|
||
tmaxHours: 24,
|
||
absorptionRateHourlyKa: 0.0373, // psp4.13099 Table 3
|
||
bioavailability: 0.8, // EMA EPAR §5.2
|
||
vdLitersPerKg: 0.09, // ~6.45 L / 70 kg per psp4.13099 (Vc + Vp)
|
||
clearanceLPerHour70kg: 0.0329, // psp4.13099 Table 3
|
||
steadyStateWeeks: 4, // EMA EPAR §5.2
|
||
compartmentModel: "two-compartment", // psp4.13099 verbatim
|
||
},
|
||
titrationStepsMg: [2.5, 5, 7.5, 10, 12.5, 15], // EMA EPAR §4.2
|
||
titrationIntervalWeeks: 4, // EMA EPAR §4.2
|
||
maxDoseMg: 15,
|
||
standardInjectionFrequency: "weekly",
|
||
indications: {
|
||
t2dm: { firstLine: false }, // adjunct, not first-line per §4.1
|
||
weightManagement: { bmiThreshold: 30 }, // §4.1 (or ≥ 27 with comorbidity)
|
||
},
|
||
storage: {
|
||
unopened: { temperatureCelsius: { min: 2, max: 8 } }, // §6.4
|
||
inUse: { temperatureCelsius: { min: 2, max: 30 }, maxDays: 30 }, // §6.3 KwikPen
|
||
},
|
||
pen: {
|
||
type: "KwikPen",
|
||
dosesPerPen: 4, // §6.5
|
||
},
|
||
sideEffects: {
|
||
veryCommon: [
|
||
"nausea",
|
||
"diarrhea",
|
||
"vomiting",
|
||
"abdominal_pain",
|
||
"constipation",
|
||
"decreased_appetite",
|
||
],
|
||
common: [
|
||
"hypoglycaemia",
|
||
"hypersensitivity",
|
||
"dizziness",
|
||
"hypotension",
|
||
"dyspepsia",
|
||
"abdominal_distension",
|
||
"eructation",
|
||
"flatulence",
|
||
"gerd",
|
||
"hair_loss",
|
||
"fatigue",
|
||
"injection_site_reaction",
|
||
"heart_rate_increased",
|
||
],
|
||
uncommon: [
|
||
"weight_decreased",
|
||
"dysgeusia",
|
||
"dysaesthesia",
|
||
"cholelithiasis",
|
||
"cholecystitis",
|
||
"acute_pancreatitis",
|
||
"delayed_gastric_emptying",
|
||
"injection_site_pain",
|
||
],
|
||
rare: ["anaphylactic_reaction", "angioedema"],
|
||
},
|
||
contraindications: ["hypersensitivity_active_substance_or_excipients"],
|
||
warnings: [
|
||
"pancreatitis_history",
|
||
"severe_gi_disease",
|
||
"diabetic_retinopathy_macular_oedema",
|
||
"pulmonary_aspiration_risk_anaesthesia",
|
||
"pregnancy_long_half_life_discontinue_one_month_before",
|
||
],
|
||
sourceEMA:
|
||
"https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf",
|
||
sourceJournal: {
|
||
citation:
|
||
"Schneck KB, Urva S. CPT Pharmacometrics Syst Pharmacol. 2024;13(3):494-503.",
|
||
doi: "10.1002/psp4.13099",
|
||
},
|
||
},
|
||
|
||
// §1.2–§1.3 — Semaglutide (Ozempic injectable, Wegovy injectable
|
||
// weight-mgmt, Rybelsus oral). EMA EPAR §5.2: half-life ≈ 1 week.
|
||
// Rybelsus is the one mixed-route brand — `brandRoutes` carries
|
||
// the oral exception while the default stays SC.
|
||
semaglutide: {
|
||
inn: "Semaglutide",
|
||
brands: ["Ozempic", "Wegovy", "Rybelsus"],
|
||
route: "subcutaneous",
|
||
brandRoutes: {
|
||
Ozempic: "subcutaneous",
|
||
Wegovy: "subcutaneous",
|
||
Rybelsus: "oral",
|
||
},
|
||
drugClass: "GLP-1 receptor agonist",
|
||
pharmacology: {
|
||
halfLifeDays: 7.0, // EMA EPAR §5.2 (≈ 1 week)
|
||
tmaxHours: 24, // EMA EPAR §5.2 (Tmax 1–3 d for SC)
|
||
absorptionRateHourlyKa: null, // EMA EPAR does not publish a pop-PK Ka
|
||
bioavailability: 0.89, // EMA Ozempic §5.2
|
||
vdLitersPerKg: 0.18, // Wegovy §5.2 (~12.4 L / 70 kg)
|
||
clearanceLPerHour70kg: 0.05, // EMA Ozempic §5.2
|
||
steadyStateWeeks: 5, // EMA EPAR §5.2 (4–5 weeks)
|
||
compartmentModel: "two-compartment", // EMA EPAR §5.2 pop-PK
|
||
},
|
||
titrationStepsMg: [0.25, 0.5, 1, 2], // Ozempic ladder §4.2
|
||
titrationIntervalWeeks: 4,
|
||
maxDoseMg: 2, // Ozempic; Wegovy max 2.4 (then 7.2)
|
||
standardInjectionFrequency: "weekly",
|
||
indications: {
|
||
t2dm: { firstLine: false }, // Ozempic — adjunct
|
||
weightManagement: { bmiThreshold: 30 }, // Wegovy ≥30 or ≥27 w/ comorbidity
|
||
},
|
||
storage: {
|
||
unopened: { temperatureCelsius: { min: 2, max: 8 } }, // §6.4
|
||
inUse: { temperatureCelsius: { min: 2, max: 30 }, maxDays: 56 }, // Ozempic §6.3
|
||
},
|
||
pen: {
|
||
type: "FlexTouch",
|
||
dosesPerPen: 4, // Ozempic 0.25/0.5 mg dose pen
|
||
},
|
||
sideEffects: {
|
||
veryCommon: ["nausea", "diarrhea", "vomiting", "abdominal_pain"],
|
||
common: [
|
||
"hypoglycaemia",
|
||
"decreased_appetite",
|
||
"dizziness",
|
||
"dyspepsia",
|
||
"constipation",
|
||
"eructation",
|
||
"flatulence",
|
||
"abdominal_distension",
|
||
"gerd",
|
||
"fatigue",
|
||
"injection_site_reaction",
|
||
"lipase_increased",
|
||
"amylase_increased",
|
||
"cholelithiasis",
|
||
],
|
||
uncommon: [
|
||
"hypersensitivity",
|
||
"dysgeusia",
|
||
"pulse_increased",
|
||
"diabetic_retinopathy_complications",
|
||
"acute_pancreatitis",
|
||
],
|
||
rare: ["anaphylactic_reaction", "angioedema"],
|
||
},
|
||
contraindications: ["hypersensitivity_active_substance_or_excipients"],
|
||
warnings: [
|
||
"pancreatitis_history",
|
||
"diabetic_retinopathy_macular_oedema",
|
||
"dehydration_risk",
|
||
"pregnancy_long_half_life_discontinue_two_months_before",
|
||
],
|
||
sourceEMA:
|
||
"https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf",
|
||
},
|
||
|
||
// §1.4 — Liraglutide (Saxenda weight-mgmt, Victoza T2DM). Daily
|
||
// SC dosing — fundamentally different cadence from the weekly
|
||
// agonists. Half-life ≈ 13 h per EMA EPAR §5.2.
|
||
liraglutide: {
|
||
inn: "Liraglutide",
|
||
brands: ["Saxenda", "Victoza"],
|
||
route: "subcutaneous",
|
||
drugClass: "GLP-1 receptor agonist",
|
||
pharmacology: {
|
||
halfLifeDays: 13 / 24, // ≈ 13 h per EMA EPAR §5.2
|
||
tmaxHours: 11, // EMA EPAR §5.2 (mean ~11 h)
|
||
absorptionRateHourlyKa: null, // not published in EMA EPAR pop-PK
|
||
bioavailability: 0.55, // EMA EPAR §5.2 (~55%)
|
||
vdLitersPerKg: 0.22, // ~22 L / 100 kg per EMA EPAR §5.2
|
||
clearanceLPerHour70kg: 1.2, // EMA EPAR §5.2 (~0.9–1.4 L/h)
|
||
steadyStateWeeks: 1, // daily, plateau within ~3 days
|
||
compartmentModel: "two-compartment",
|
||
},
|
||
titrationStepsMg: [0.6, 1.2, 1.8, 2.4, 3.0], // Saxenda §4.2
|
||
titrationIntervalWeeks: 1, // Saxenda: +0.6 mg/week
|
||
maxDoseMg: 3.0, // Saxenda; Victoza max 1.8
|
||
standardInjectionFrequency: "daily",
|
||
indications: {
|
||
t2dm: { firstLine: false }, // Victoza — adjunct
|
||
weightManagement: { bmiThreshold: 30 }, // Saxenda
|
||
},
|
||
storage: {
|
||
unopened: { temperatureCelsius: { min: 2, max: 8 } },
|
||
inUse: { temperatureCelsius: { min: 2, max: 30 }, maxDays: 30 },
|
||
},
|
||
pen: {
|
||
type: "Pre-filled pen",
|
||
dosesPerPen: null, // continuous-dial pen, doses vary
|
||
},
|
||
sideEffects: {
|
||
veryCommon: ["nausea", "vomiting", "diarrhea", "constipation"],
|
||
common: [
|
||
"hypoglycaemia",
|
||
"decreased_appetite",
|
||
"headache",
|
||
"dizziness",
|
||
"dyspepsia",
|
||
"abdominal_pain",
|
||
"gerd",
|
||
"abdominal_distension",
|
||
"eructation",
|
||
"flatulence",
|
||
"fatigue",
|
||
"injection_site_reaction",
|
||
"asthenia",
|
||
],
|
||
uncommon: [
|
||
"dehydration",
|
||
"cholelithiasis",
|
||
"cholecystitis",
|
||
"acute_pancreatitis",
|
||
"tachycardia",
|
||
],
|
||
rare: ["anaphylactic_reaction", "angioedema", "acute_renal_failure"],
|
||
},
|
||
contraindications: ["hypersensitivity_active_substance_or_excipients"],
|
||
warnings: [
|
||
"pancreatitis_history",
|
||
"thyroid_disease",
|
||
"dehydration_risk",
|
||
"pregnancy_not_recommended",
|
||
],
|
||
sourceEMA:
|
||
"https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf",
|
||
},
|
||
|
||
// §1.5 — Dulaglutide (Trulicity). Weekly SC, half-life ~5 d per
|
||
// EMA EPAR §5.2. SC bioavailability ~47–65%.
|
||
dulaglutide: {
|
||
inn: "Dulaglutide",
|
||
brands: ["Trulicity"],
|
||
route: "subcutaneous",
|
||
drugClass: "GLP-1 receptor agonist",
|
||
pharmacology: {
|
||
halfLifeDays: 5.0, // EMA EPAR §5.2
|
||
tmaxHours: 48, // EMA EPAR §5.2 (Tmax 24–72 h)
|
||
absorptionRateHourlyKa: null, // not published in EMA EPAR pop-PK
|
||
bioavailability: 0.47, // EMA EPAR §5.2 (47% min of 47–65% range)
|
||
vdLitersPerKg: 0.27, // EMA EPAR §5.2 (Vc/F ~19.2 L → ~0.27 L/kg)
|
||
clearanceLPerHour70kg: 0.107, // EMA EPAR §5.2 (~0.107 L/h)
|
||
steadyStateWeeks: 2, // EMA EPAR §5.2 (~2 weeks)
|
||
compartmentModel: "two-compartment",
|
||
},
|
||
titrationStepsMg: [0.75, 1.5, 3.0, 4.5], // EMA EPAR §4.2
|
||
titrationIntervalWeeks: 4,
|
||
maxDoseMg: 4.5,
|
||
standardInjectionFrequency: "weekly",
|
||
indications: {
|
||
t2dm: { firstLine: false }, // adjunct
|
||
weightManagement: { bmiThreshold: null }, // not approved for weight mgmt
|
||
},
|
||
storage: {
|
||
unopened: { temperatureCelsius: { min: 2, max: 8 } },
|
||
inUse: { temperatureCelsius: { min: 2, max: 30 }, maxDays: 14 }, // EMA §6.3
|
||
},
|
||
pen: {
|
||
type: "Single-dose pen",
|
||
dosesPerPen: 1, // disposable single-dose
|
||
},
|
||
sideEffects: {
|
||
veryCommon: ["nausea", "diarrhea", "vomiting", "abdominal_pain"],
|
||
common: [
|
||
"hypoglycaemia",
|
||
"decreased_appetite",
|
||
"dyspepsia",
|
||
"constipation",
|
||
"flatulence",
|
||
"abdominal_distension",
|
||
"gerd",
|
||
"eructation",
|
||
"fatigue",
|
||
"injection_site_reaction",
|
||
"sinus_tachycardia",
|
||
"first_degree_av_block",
|
||
],
|
||
uncommon: ["cholelithiasis", "cholecystitis", "acute_pancreatitis"],
|
||
rare: ["anaphylactic_reaction", "angioedema"],
|
||
},
|
||
contraindications: ["hypersensitivity_active_substance_or_excipients"],
|
||
warnings: [
|
||
"pancreatitis_history",
|
||
"severe_gi_disease",
|
||
"diabetic_retinopathy_macular_oedema",
|
||
"dehydration_risk",
|
||
],
|
||
sourceEMA:
|
||
"https://www.ema.europa.eu/en/documents/product-information/trulicity-epar-product-information_en.pdf",
|
||
},
|
||
|
||
// Exenatide — twin product lines: Byetta (IR, twice-daily,
|
||
// t½ ~2.4 h) and Bydureon (extended-release, weekly,
|
||
// terminal t½ ~2 weeks). The record captures the IR profile as
|
||
// the default; the brand list flags Bydureon as the ER variant.
|
||
// The standard frequency reflects the IR formulation; Bydureon
|
||
// consumers must consult the Bydureon-specific EPAR for cadence.
|
||
exenatide: {
|
||
inn: "Exenatide",
|
||
brands: ["Byetta", "Bydureon"],
|
||
route: "subcutaneous",
|
||
drugClass: "GLP-1 receptor agonist",
|
||
pharmacology: {
|
||
halfLifeDays: 2.4 / 24, // Byetta IR — ~2.4 h per EMA EPAR §5.2
|
||
tmaxHours: 2.1, // EMA Byetta §5.2 (median ~2 h)
|
||
absorptionRateHourlyKa: null, // not published
|
||
bioavailability: 0.65, // EMA Byetta §5.2 (~65%)
|
||
vdLitersPerKg: 0.4, // EMA Byetta §5.2 (~28 L / 70 kg)
|
||
clearanceLPerHour70kg: 9.1, // EMA Byetta §5.2 (~9.1 L/h)
|
||
steadyStateWeeks: 1,
|
||
compartmentModel: "two-compartment",
|
||
},
|
||
titrationStepsMg: [0.005, 0.01], // Byetta 5 µg → 10 µg twice daily
|
||
titrationIntervalWeeks: 4, // Byetta §4.2 (escalate after ≥4 wk)
|
||
maxDoseMg: 0.01,
|
||
standardInjectionFrequency: "twice-daily",
|
||
indications: {
|
||
t2dm: { firstLine: false }, // adjunct only
|
||
weightManagement: { bmiThreshold: null }, // not approved for weight mgmt
|
||
},
|
||
storage: {
|
||
unopened: { temperatureCelsius: { min: 2, max: 8 } },
|
||
inUse: { temperatureCelsius: { min: 2, max: 25 }, maxDays: 30 }, // Byetta §6.3
|
||
},
|
||
pen: {
|
||
type: "Pre-filled pen (Byetta) / weekly suspension (Bydureon)",
|
||
dosesPerPen: 60, // Byetta 60 doses per pen
|
||
},
|
||
sideEffects: {
|
||
veryCommon: [
|
||
"hypoglycaemia",
|
||
"nausea",
|
||
"vomiting",
|
||
"diarrhea",
|
||
],
|
||
common: [
|
||
"decreased_appetite",
|
||
"dizziness",
|
||
"headache",
|
||
"dyspepsia",
|
||
"abdominal_pain",
|
||
"gerd",
|
||
"flatulence",
|
||
"abdominal_distension",
|
||
"constipation",
|
||
"eructation",
|
||
"hyperhidrosis",
|
||
"injection_site_reaction",
|
||
"fatigue",
|
||
],
|
||
uncommon: [
|
||
"dehydration",
|
||
"cholelithiasis",
|
||
"acute_pancreatitis",
|
||
"renal_failure",
|
||
],
|
||
rare: ["anaphylactic_reaction", "angioedema"],
|
||
},
|
||
contraindications: [
|
||
"hypersensitivity_active_substance_or_excipients",
|
||
"severe_renal_impairment_egfr_below_30",
|
||
],
|
||
warnings: [
|
||
"pancreatitis_history",
|
||
"severe_gi_disease",
|
||
"renal_impairment",
|
||
"pregnancy_not_recommended",
|
||
],
|
||
sourceEMA:
|
||
"https://www.ema.europa.eu/en/documents/product-information/byetta-epar-product-information_en.pdf",
|
||
},
|
||
} as const;
|
||
|
||
/**
|
||
* Resolve the route for a given drug + brand. Falls back to the
|
||
* record default when no per-brand override is registered. Read by
|
||
* the glp1-knowledge test suite.
|
||
*/
|
||
export function routeForBrand(
|
||
drugId: Glp1DrugId,
|
||
brand: string,
|
||
): Glp1Route | null {
|
||
const record = GLP1_DRUGS[drugId];
|
||
if (!record) return null;
|
||
if (!record.brands.includes(brand)) return null;
|
||
if (record.brandRoutes && brand in record.brandRoutes) {
|
||
return record.brandRoutes[brand];
|
||
}
|
||
return record.route;
|
||
}
|
||
|
||
/**
|
||
* Lookup helper — given an arbitrary brand string, find the drug
|
||
* record that lists it (case-insensitive). Returns null when the
|
||
* brand is unknown; useful for connecting free-text medication
|
||
* names to the catalog.
|
||
*/
|
||
export function findDrugByBrand(brand: string): Glp1DrugRecord | null {
|
||
const needle = brand.trim().toLowerCase();
|
||
if (!needle) return null;
|
||
for (const record of Object.values(GLP1_DRUGS)) {
|
||
if (record.brands.some((b) => b.toLowerCase() === needle)) {
|
||
return record;
|
||
}
|
||
}
|
||
return null;
|
||
}
|
||
|
||
/**
|
||
* Lookup helper — given an arbitrary brand string, find the drug ID
|
||
* (catalog key) that lists it. Combines `findDrugByBrand` with the
|
||
* `GLP1_DRUGS` reverse-lookup pattern previously hand-rolled in the
|
||
* DrugLevelChart and the titration route. Returns null when the brand
|
||
* is unknown.
|
||
*/
|
||
export function findDrugIdByBrand(brand: string): Glp1DrugId | null {
|
||
const record = findDrugByBrand(brand);
|
||
if (!record) return null;
|
||
for (const [id, candidate] of Object.entries(GLP1_DRUGS)) {
|
||
if (candidate === record) return id as Glp1DrugId;
|
||
}
|
||
return null;
|
||
}
|
||
|
||
/**
|
||
* The catalog's drug-ids in stable order. Read by the GLP-1 PK +
|
||
* ladder test suites so a future drug addition flows through the
|
||
* verification matrix without a hand-rolled list.
|
||
*/
|
||
export const GLP1_DRUG_IDS: readonly Glp1DrugId[] = [
|
||
"tirzepatide",
|
||
"semaglutide",
|
||
"liraglutide",
|
||
"dulaglutide",
|
||
"exenatide",
|
||
] as const;
|
||
|